Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chia-Chi Lin

Showing results (171-180 of 231) with videos related to

Pageof 24
Sort By:
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
Investigational New Drugs|June 4, 2025
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumorsNai-Jung Chiang, Li-Yuan Bai, I-Wei Ho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2020
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLCViola W Zhu, Yen-Ting Lin, Dong-Wan Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2015
Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell CarcinomaJhe-Cyuan Guo, Ta-Chen Huang, Chia-Chi Lin, et al.
The Oncologist|December 8, 2020
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell TumorsJames H Lewis, Hans Gelderblom, Michiel van de Sande, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 17, 2020
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 TrialLuis Paz-Ares, Tae Min Kim, David Vicente, et al.
The Oncologist|January 2, 2019
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular CarcinomaImane El Dika, Ho Yeong Lim, Wei Peng Yong, et al.
Cancer Chemotherapy and Pharmacology|September 17, 2008
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumorsChia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 25, 2014
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancerJih-Hsiang Lee, Yu-Lin Lin, Wei-Hsun Hsu, et al.
Journal for Immunotherapy of Cancer|June 8, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignanciesAung Naing, Chia-Chi Lin, Manish R Patel, et al.
Pageof 24

Showing results (171-180 of 231) with videos related to

Sort By:
Pageof 24
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
Investigational New Drugs|June 4, 2025
A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumorsNai-Jung Chiang, Li-Yuan Bai, I-Wei Ho, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2020
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLCViola W Zhu, Yen-Ting Lin, Dong-Wan Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2015
Postchemoradiotherapy Pathologic Stage Classified by the American Joint Committee on the Cancer Staging System Predicts Prognosis of Patients with Locally Advanced Esophageal Squamous Cell CarcinomaJhe-Cyuan Guo, Ta-Chen Huang, Chia-Chi Lin, et al.
The Oncologist|December 8, 2020
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell TumorsJames H Lewis, Hans Gelderblom, Michiel van de Sande, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 17, 2020
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 TrialLuis Paz-Ares, Tae Min Kim, David Vicente, et al.
The Oncologist|January 2, 2019
An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular CarcinomaImane El Dika, Ho Yeong Lim, Wei Peng Yong, et al.
Cancer Chemotherapy and Pharmacology|September 17, 2008
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumorsChia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 25, 2014
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancerJih-Hsiang Lee, Yu-Lin Lin, Wei-Hsun Hsu, et al.
Journal for Immunotherapy of Cancer|June 8, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignanciesAung Naing, Chia-Chi Lin, Manish R Patel, et al.
Pageof 24